Men's Health News

RSS

DiagnoCure’s PCA3 prostate cancer diagnostic test showcased at AUA meeting

DiagnoCure Inc., a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the American Urological Association (AUA) meeting in Atlanta, GA.

25 May 2012

Doctors disagree on new prostate cancer screening guidelines

One doctor suggests the problem is the rush to treatment, not the screening; another suggests that a failure to screen men could be more costly in the long run.

25 May 2012

Oestrogen promotes presence of 'mucoid' form of P. aeruginosa in women with CF

Researchers from the Respiratory Research Division of the Department of Medicine, Royal College of Surgeons in Ireland (RCSI) have published a study which represents a major breakthrough in understanding why females with cystic fibrosis do worse than males.

25 May 2012

Scientists discover key gene essential for sperm development

A new type of male contraceptive could be created thanks to the discovery of a key gene essential for sperm development.

25 May 2012

Auxilium, FCB I file suit against Watson over generic Testim

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim 1%.

25 May 2012

Cancer diagnosis may increase risk of death in men with mental illness

Men suffering from psychiatric problems when diagnosed with cancer are more likely to die from the disease, according to a new study published today in the British Journal of Cancer.

24 May 2012

Breakthrough in understanding the causes of unexplained male infertility

The diagnosis of male fertility is usually performed through the observation of the sperm in the microscope. However, a normal quality semen does not guarantee an adequate fertility. In fact, there is a considerable proportion of cases of unexplained infertility and data suggest that abnormal sperm function may have a genetic or molecular origin.

24 May 2012

CMS sticks with Medicare coverage of PSA test

The federal government is not changing coverage plans "at this time." Meanwhile, a number of urologists and other medical specialists raise concerns that new recommendations against prostate cancer screening will hurt men's health.

24 May 2012

Viewpoints: The promise and perils of prostate screening; Presidential candidates shy away from frank discussion of spending

After an exhaustive process, the U.S. Preventive Services Task Force has announced its final recommendation on PSA-based prostate cancer screening. It finds that the known harms of screening outweigh the potential benefits for men who have no cancer symptoms. It notes that all screening studies have demonstrated considerable harms associated with screening, but only one major study found evidence that screening saves lives -- and that study has some internal inconsistencies.

24 May 2012

Federal task force recommends dropping routine prostate cancer test

The U.S. Preventive Services Task Force finds scant evidence that the PSA blood test saves lives and instead says unneeded treatment leads to serious problems, including impotence and incontinence.

23 May 2012

Article examines reasons why people are so reluctant to give up PSA test

The uproar that began last year when the U.S. Preventive Services Task Force stated that doctors should no longer offer regular prostate-cancer tests to healthy men continued this week when the task force released their final report. Overall, they stuck to their guns, stating that a blood test commonly used to screen for prostate cancer, the PSA test, causes more harm than good - it leads men to receive unnecessary, and sometimes even dangerous, treatments.

23 May 2012

MDxHealth announces availability of ConfirmMDx for Prostate Cancer test

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

23 May 2012

Women and their loved ones are affected by gout: Survey

An online survey conducted by Red Hot Mamas North America, Inc. found that women and their loved ones are significantly affected by very painful bouts of gout, which they consider to be chronic and severe. Respondents indicated that although the debilitating pain associated with the condition affects quality of life, many individuals are prescribed medications meant to control the condition which they are not taking.

23 May 2012

LUGPA discredits recommendations by USPSTF to stop prostate cancer testing

The Large Urology Group Practice Association (LUGPA), representing more than 1,800 urologists, today discredited recommendations by the U.S. Preventive Services Task Force (USPSTF) to stop prostate cancer testing.

22 May 2012

USPSTF issues final recommendation statement against PSA testing

The Prostate Cancer Roundtable expressed deep disappointment today as the U.S. Preventive Services Task Force (USPSTF) issued its final recommendation statement against the use of prostate-specific antigen (PSA) testing in the detection of prostate cancer.

22 May 2012

Male cyclists may experience hormonal imbalances that affect reproductive health

A new study conducted by UCLA School of Nursing researchers has found that serious leisure male cyclists may experience hormonal imbalances that could affect their reproductive health. The study, "Reproductive Hormones and Interleukin-6 in Serious Leisure Male Athletes," was published in the European Journal of Applied Physiology.

21 May 2012

Treatment of early stage prostate cancer can also result in improved QOL for men with LUTS

Treatment of early stage prostate cancer can also result in improved quality of life for a subgroup of men who suffer from lower urinary tract symptoms (LUTS), according to an abstract of a Beth Israel Deaconess Medical Center-led study presented to the American Urological Association.

21 May 2012

Study uncovers distinct subtype of prostate cancer

A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers at Weill Cornell Medical College, the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute.

21 May 2012

Osteopenia/osteoporosis more prevalent among male patients with pulmonary disease

There is a very high prevalence of osteopenia/osteoporosis among male patients with pulmonary disease, according to a new study from researchers in California.

21 May 2012

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012